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Alopecia areata (AA) is an immune-mediated disease 
causing temporary or permanent hair loss. Up to 46% 
of patients with AA also have nail involvement. The 
aim of this study was to determine the presence, ty-
pes, and clinical implications of nail changes in pa-
tients with AA. This questionnaire-based survey eva-
luated 256 patients with AA. General demographic 
variables, specific nail changes, nail-related quality of 
life (QoL), and treatment history and need were evalu-
ated. Prevalence of nail involvement in AA was 64.1%. 
The specific nail signs reported most frequently were 
pitting (29.7%, p = 0.008) and trachyonychia (18.0%). 
Red spots on the lunula were less frequent (5.1%), 
but very specific for severe AA. Nail-related QoL was 
only minimally affected by nail changes. In conclusion, 
nail involvement is common in patients with AA and 
presents mostly with pitting and trachyonychia. The 
presence of these nail changes reflects the severity of 
the disease, with red spots on the lunula as a predictor 
for severe alopecia. 
Key words: alopecia areata; quality of life; prevalence; nail di-
sease; survey.
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Alopecia areata (AA) is an immune-mediated disease that is characterized by non-scarring hair loss. The 
disease may be limited to one or more discrete, well-
circumscribed round or oval patches of hair loss on the 
scalp or body (alopecia areata focalis; AAF), or it may 
affect the entire scalp (alopecia areata totalis; AAT), or 
even the entire body (alopecia areata universalis; AAU). 
The natural course of the disease is unpredictable, but 
often benign. Spontaneous regrowth of hair occurs in 80% 
of patients within the first year, but relapses at any given 
time are not uncommon. Poor prognostic factors include 
bald patches persisting for more than one year, onset of 
hair loss before puberty, a positive family history of AA, 
ophiasis pattern, associated nail changes, atopy, and Down 
syndrome (1). Severity of AA at onset is perhaps the 
most important negative prognostic factor (2). A lifetime 
incidence between 0.57% and 3.8% has been reported 
in hospital-based studies worldwide (3). AA may appear 
at any age, but as many as 60% of patients with AA will 
present with their first patch before 20 years of age (4), and 
prevalence peaks between the 2nd and 4th decades of life (1).
AA is a lymphocyte cell-mediated inflammatory form 
of hair loss in which a complex interplay between genetic 
factors and underlying autoimmune aetiopathogenesis 
is suggested, although the exact aetiological pathway is 
unknown (5). Some studies have shown association with 
other auto-immune diseases, including asthma, atopic 
dermatitis, and vitiligo (6).
Many patients with AA also have nail involvement, 
with a reported incidence ranging from 9% to 46% (7, 
8). Incidence is much lower in patients with focal AA 
than in patients with severe forms of AA (9, 10), and may 
be higher in children than in adults (8, 11). Nail changes 
may either precede the hair loss or occur months or years 
later, and may persist even after hair regrowth. The patho-
genic mechanism of nail changes in AA is unknown, but 
it has been proposed that because the nails are similar in 
structure and growth to hair follicles, they are affected 
by the same inflammatory reaction that targets hair fol-
licles in AA. Histopathological observations using light 
and electron microscopic techniques show that most of 
the nail changes in AA are found within the proximal 
matrix, and are less pronounced in the distal matrix, 
and negligible in the nail bed (12). The fact that the nail 
matrix is far more often involved than the nail bed results 
in a clinical presentation of matrix-derived nail changes 
that may include pitting, trachyonychia, onychorrhexis, 
Beau’s lines, onychomadesis, and nail thinning with or 
without koilonychia (8). Anonychia and scarring are not 
typically seen. Red spots on the lunula are rarely present, 
but are highly suggestive for the diagnosis AA (13). Nail 
bed signs are uncommon and only one case of severe 
onycholysis has been reported to date (14). 
Studies in the field of nail changes in patients with 
AA are sparse. The aim of this study was to evaluate 
nail involvement in patients with AA, the impact on 
quality of life (QoL), and to evaluate a potential unmet 
need for treatment. 
MATERIALS AND METHODS
Patients
This study was conducted in collaboration with the Dutch 
Alopecia Patient Association between April 2013 and October 
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2013. A questionnaire was distributed to all 930 members of 
the alopecia association, together with a letter inviting partici-
pation and explaining the purpose of the study, and reply-paid 
envelopes. The questionnaire was completed anonymously and 
no incentives were given. It contained questions concerning 
general demographic variables, QoL, and specific nail changes 
thought to be attributed to AA. Also, patients experience of 
current and previous treatments for the nails were assessed. 
Nail signs assumed to be due to AA, i.e. pitting, trachyonychia, 
leukonychia, crumbling, red spots on the lunula, and koilonychia 
were illustrated with photographs. Based on these photographs, 
patients could indicate which of these nail features were present. 
If patients had other nail changes, they could report these in their 
own words, and these were categorized later by an experienced 
dermatologist. QoL was assessed using the nail psoriasis QoL 
scale (NPQ10), a questionnaire primarily developed and valida-
ted to measure QoL in patients with nail psoriasis (15). This scale 
was used unmodified for the measurement of QoL for patients 
with AA with nail involvement. The first question concerns the 
pain intensity of nail changes and the other 9 questions concern 
the functional impairment caused by their nail involvement in 
daily life. Each response is scored from 0 to 2, with the response 
“not” and “never” scoring 0, “sometimes” and “a little” scoring 
1, and “very” and “always” scoring 2 points. The question con-
cerning the interference of nail changes with the ability to drive 
a car was removed because the target population also included 
minors. The NPQ10 scale used therefore has a range from 0 
(no impairment of QoL) to 18 (maximum impairment of QoL). 
Statistical analysis
Data were entered in a database and statistical analysis was sub-
sequently performed using Statistical Package for Social Sciences 
(SPSS 20.0, IBM Corp, Armonk, NY, USA). Descriptive statistics 
were provided using mean ± standard deviation (SD) and median 
(range) for normally and non-parametrically 
distributed numerical values, respectively. 
Frequencies and percentages were used for 
categorical variables. Missing values were 
not included to calculate percentages. Con-
tinuous variables with normal distribution 
were tested by unpaired t-test and the results 
are presented as mean ± SD. Categorical 
variables were represented by frequencies 
and percentages and analysed by χ2 or 
Fisher’s exact test. Missing values were 
not included in calculations of percentages. 
Statistical analysis of more than 2 means 
was performed with one-way analysis of 
variance (ANOVA). Statistical significance 
was considered at a level of 5% (p < 0.05) 
for all tests. 
RESULTS
Patients and characteristics 
A total of 930 questionnaires were distributed and 347 
were returned within 6 months, a response rate of 37.3%. 
Most patients (88.2%) had AA. Other respondents 
had other types of alopecia, mostly pattern hair loss 
(PHL; 8.7%). Fifty questionnaires from patients with 
AA were excluded because the questions concerning 
nail involvement were not completed, resulting in 256 
questionnaires from patients with AA that were available 
for analysis. The 30 questionnaires from patients with 
PHL served as controls, because nail involvement has 
not been reported in these patients, while questionnaires 
from patients with cicatricial alopecia, telogen effluvium, 
and trichotillomania were excluded because of their low 
prevalence. Also, questionnaires from patients with AA 
diffusa were excluded because it was considered that 
some patients might not have been able to discriminate 
between this type of AA and other more diffuse forms 
of non-scarring alopecia.
Patient characteristics
The distribution of patient characteristics is shown in 
Table I. Most patients had severe AA: 74.6% had AAT 
or AAU, while 25.4% had AAF. A vast majority of re-
spondents were female (83.8%), and a small majority of 
respondents (64.1%) had experienced nail involvement 
Table I. Characteristics of patients with and without nail involvement in alopecia areata (AA) and the control group (pattern hair loss, PHL) 
Patients with AA 
(n = 256)
Patients with AA with nail 
involvement (n = 164)
Patients with AA without 
nail involvement (n = 92) p-value*
Controls 
(n = 30)
Sex, n (%)
  Female 212 (83.8) 131 (80.4) 81 (90.0) 0.056 30 (100)
  Male 41 (16.2) 32 (19.6) 9 (10.0) 0
  Missing 3 1 2 0
Age, years, mean ± SD 48.5 ± 13.6 49.0 ± 14.9 47.7 ± 11.9 0.015 52.2 ± 14.7
Age of onset alopecia, years, mean ± SD 25.9 ± 16.1 26.5 ± 16.7 24.9 ± 15.0 0.181 28.6 ± 14.1
Type of alopecia, n (%)
 Alopecia areata focalis (AAF) 65 (25.4) 35 (21.3) 30 (32.6) 0.061 –
 Alopecia areata totalis (AAT) 42 (16.4) 22 (13.4) 20 (21.7) 0.084 –
 Alopecia areata universalis (AAU) 149 (58.2) 107** (65.2) 42 (45.7) 0.002 –
*Patients with AA with nail involvement vs. patients with AA without nail involvement. **p-value of AAU group vs. AAT/AAF combined, p = 0.002.
Table II. Characteristics of patients with nail changes divided into the 3 forms of alopecia
All AA 
(n = 164)
AAF
(n = 35)
AAT
(n = 22)
AAU
(n = 107) p-value*
Age of onset nail changes, years, mean ± SD 34.4 ± 17.2 30.7 ± 18.2 29.1 ± 17.7 36.4 ± 16.5 0.294
Duration nail changes, years, mean ± SD 4.9 ± 8.5 3.6 ± 3.2 9.8 ± 10.3 4.9 ± 9.1 0.865
Localization of nail changes, n (%)
  Fingernails only 88 (54.0) 18 (53.0) 11 (52.4) 56 (53.8) 0.980
0.001
0.053
  Toenails only 20 (12.3) 6 (17.6) 7 (33.3) 6 (5.8)
  Both 55 (33.7) 10 (29.4) 3 (14.3) 42 (40.4)
  Unknown 1 1 1 3
Number of nails affected, n (SD)
  Number of fingernails 6.84 (3.4) 6.70 (3.9) 7.00 (3.4) 6.92 (3.3) 0.906
  Number of toenails 4.59 (3.4) 3.00 (1.2) 3.17 (3.4) 8.20 (2.7) 0.009
*Results of analysis of variance (ANOVA) comparing the 3 groups: alopecia areata focalis (AAF), alopecia 
areata totalis (AAT), and alopecia areata universalis (AAU).
SD: standard deviation.
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at any time during the course of their AA. The incidence 
of nail abnormalities in the control group was 36.6%, 
which is significantly lower than among any group of 
patients with AA (p = 0.007). More than 65% of patients 
with AA with nail involvement had AAU (p = 0.002), 
while most patients without nail involvement (54.3%) 
had milder forms of AA. There was a tendency for nail 
involvement to be more frequent in males than in females 
(p = 0.056). The mean age ± SD of the respondents with 
AA was 48.5 ± 13.6 years. Patients with nail involvement 
were slightly older than those with AA without nail 
involvement. The mean age of onset of hair loss was 
25.9 ± 16.1 years without significant differences between 
patients with AA with and without nail involvement. Nail 
changes developed, a mean of 7.9 years later than the 
alopecia (Table II). 
In over half of the patients with AA, only the finger-
nails were involved. Isolated involvement of the toenails 
was reported in 1 out of 8 patients with AA, while invol-
vement of both toenails and fingernails was reported by 
one-third of respondents. The mean number of involved 
fingers was 7, and was similar among all 3 groups of 
patients with AA (p = 0.90), while the mean number of 
involved toenails was higher among patients with AAU 
than among those with AAF or AAT (p = 0.009).
Patient-reported nail changes 
A total of 164 patients with AA reported that their nails 
had been affected at some time during the course of 
the disease. This corresponds to 64.1% of the returned 
complete questionnaires. The reported nail signs are 
shown in Table III and were compared with the control 
PHL group. 
Pitting, crumbling, leukonychia, and trachyonychia 
are the most commonly observed nail changes in AA. 
Of these, leukonychia and crumbling were also reported 
in rather high percentages in the control group. Koilo-
nychia (3.1%) and red spots on the lunula (5.1%) were 
reported in a few patients with AA, but in none of the 
control patients. Brittleness, splitting, onychorrhexis, 
and onychoschizia are signs of brittle nail syndrome 
and were reported in approximately 10% of both the 
patients with AA and the controls. Onycholysis, slow 
nail growth, disappearing lunula, and onychomadesis 
were all reported once in AA (n = 1, 0.4%). 
All nail features were reported more frequently in 
patients with AAU than in patients with AAF/AAT, but 
this difference was significant only for red spots on the 
lunula (p = 0.04). 
Quality of life
The results for nail-related QoL are shown in Table IV 
(NPQ10). The mean NPQ10 of patients with nail changes 
and mean ± SD AA score was 0.91 ± 1.61. There was no 
significant difference between sex and QoL (NPQ10 was 
0.84 in males and 0.92 in females, respectively). There 
was a tendency to a higher impairment score in patients 
with both toenail and fingernail involvement, compa-
red with patients with only fingernail or only toenail 
involvement. (NPQ10 was 1.07, 0.88, 0.86, respecti-
vely, p = 0.066). Looking at the activities or complaints 
separately, patients with nail involvement were most 
restricted in putting on socks. The results in NPQ10 of 
the control patients were not significantly different from 
those with AA (data not shown). The mean NPQ10 in 
this group was 1.40. Similar to patients with AA, putting 
Table III. Nail signs in patients with alopecia areata (AA) compared 
with control group (pattern hair loss, PHL)
All AA
n = 256
n (%)
AAF/AAT
n = 107
n (%)
AAU
n = 149
n (%)
Controls
n = 30
n (%) p-valuea
Nail involvement 164 (64.1) 57 (53.3) 107 (71.8) 11 (36.6) 0.007
Sign
  Pitting 76 (29.7) 17 (15.9) 59 (39.6) 2 (6.7) 0.008
  Trachyonychia 46 (18.0) 12 (11.2) 34 (22.8) 2 (6.7) 0.193
  Leukonychia 63 (24.6) 22 (20.6) 41 (27.5) 4 (13.3) 0.253
  Crumbling 68 (26.6) 21 (19.6) 47 (31.5) 6 (20.0) 0.578
  Red spots lunula 13 (5.1) 1 (0.9) 12 (8.1) 0 0.373
  Koilonychia 8 (3.1) 2 (1.9) 6 (4.0) 1 (3.3) 1.000
  Beau’s lines 2 (0.8) 0 2 (1.3) 0 1.000
  Ridging 23 (9.0) 7 (6.5) 16 (10.7) 1 (3.3) 0.488
  Onychorrhexis 8 (3.1) 3 (2.8) 5 (3.4) 0 1.000
  Onychoschizia 9 ( (3.5) 3 (2.8) 6 (4.0) 1 (3.3) 1.000
  Onychomadesis 1 (0.4) 1 (0.9) 0 0 1.000
  Disappearing lunula 1 (0.4) 0 1 (0.7) 0 1.000
  Slow growth 1 (0.4) 1 (0.9) 0 0 1.000
  Brittle nails 10 (3.9) 5 (4.7) 5 (3.4) 1 (3.3) 1.000
  Onycholysis 3 (1.2) 1 (0.9) 2 (1.3) 0 1.000
  Unclassifiable 7 (2.7) 3 (2.8) 4 (2.7) 2 (6.7) 0.241
aAll AA vs. controls.
AAF: alopecia areata focalis; AAT: alopecia areata totalis; AAU: alopecia areata 
universalis.
Table IV. Nail-specific quality of life results (NPQ10)
Very painful A little painful Not painful No data 
1. My nail changes are painful 2 (1.3) 24 (15.2) 132 (83.5) 98 
Always Sometimes Never No data 
2. Because of my nail changes I have trouble putting on my shoes – 18 (11.5) 139 (88.5) 99 
3. Because of my nail changes I have trouble performing household chores 2 (1.3) 26 (16.5) 130 (82.3) 98 
4. Putting on clothes takes longer than normal because of my nail changes – 9 (5.7) 149 (94.3) 98 
5. I have trouble putting on socks because of my nail changes 4 (2.5) 28 (17.7) 126 (79.7) 98 
6. I have trouble turning the latchkey because of my nail changes – 5 (3.2) 153 (96.8) 98 
7. Other people help me to dress myself because of my nail changes – 1 (0.6) 156 (99.4) 99 
8. I avoid chores around the house because of my nail changes – 11 (7.0) 146 (93.0) 99 
9. I am more crabby and irritated because of my nail changes – 10 (6.3) 148 (93.7) 98
A
ct
aD
V
A
ct
aD
V
A
d
v
a
n
c
e
s 
in
 d
e
rm
a
to
lo
g
y
 a
n
d
 v
e
n
e
re
o
lo
g
y
A
c
ta
 D
e
rm
a
to
-V
e
n
e
re
o
lo
g
ic
a
215Nail involvement in alopecia areata
Acta Derm Venereol 2018
on socks was also the problem most often encountered 
the control group. 
Treatment of nail changes 
Twenty-two (13.8%) of the 164 patients with AA with 
nail involvement indicated having received any treat-
ment for their nail disorder. Topical corticosteroids were 
mentioned by 4 patients, tar ointment by one, topical 
chlorhexidine cream by one, an unspecified cream/
ointment by 2 patients, and intralesional steroids by one 
patient. Oral treatments included biotin (n = 2), vitamin 
B complex (n = 1), vitamin D (n = 1), vitamin E (n = 1), 
and antifungals (n = 8). Other systemic treatments, inclu-
ding oral corticosteroids, methotrexate, or cyclosporine 
were not reported. Of all mentioned therapies, 8 patients 
experienced positive treatment results with vitamin B 
complex (n = 1), vitamin D (n = 1), vitamin E (n = 1), 
biotin (n = 2), chlorhexidine cream (n = 1), nail hardener 
(n = 1), and pedicure treatment (n = 1). 
Unmet needs
Patients were asked about their desire for effective treat-
ment of nail changes caused by AA. If patients had not 
received treatment in the past, they were asked about their 
desire to have treatment. Thirty-five percent reported a 
desire for such a treatment, while 65% considered their 
nail abnormalities too limited to justify any treatment. 
Furthermore, 76.9% of patients with nail changes had 
no confidence in the effectiveness of available treatment 
options, 28.7% thought that treatment would be uncom-
fortable, and 39.8% of the patients assumed it would 
be time-consuming. Fig. 1 shows the amount of time 
patients reported being willing to spend on treatment of 
their nails per day. Most patients wanted to spend less 
than 5 min per day. Less than 10% were willing to spend 
more than 15 min per day in order to improve their nails. 
DISCUSSION
Nail changes occur frequently in patients with AA and 
indicate a poor prognostic factor (7). The aim of this 
study was to evaluate the prevalence and signs of nail 
involvement in patients with AA, the impact on QoL, and 
to evaluate a potential unmet need for treatment. Our re-
sults showed nail involvement in most patients with AA, 
more frequently in patients with AAU than in patients 
with AAF. Pitting, leukonychia, and trachyonychia were 
reported most often, but red spots on the lunula appear to 
be most specific for (severe) AA. QoL in patients with AA 
was only minimally affected by their nail changes. The 
nail-specific unmet medical needs appeared to be low, 
possibly due to lack of awareness of therapeutic options.
Among the 256 respondents in this study, nail invol-
vement was reported in 64.1%. Severity of alopecia was 
a major determinant in reported incidence. Nail invol-
vement was reported in 53.8% (35/65) of patients with 
AAF, while 71.8% (107/149) of the patients with AAU 
reported nail involvement. Patients with PHL were in-
cluded as controls because nail involvement has not been 
reported in these patients. Also, among these controls, 
nail signs were reported relatively frequently, in 36.6% 
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Fig. 1. The time patients with alopecia areata are willing to spend 
treating their nail abnormalities.
Table V. Literature overview of nail signs in patients with alopecia areata 
This study
Tosti et al. 
1994 (8)
Sharma et al. 
1998 (11)
Garcia-
Hernandez 
et al. 1999 
(16)
Tan et al. 
2002 (5)
Gandhi et 
al. 2003 
(17)
Goh et 
al. 2006 
(18)
Kasumagic-
Halilovoc & 
Prohic 2009 
(10)
Cho et 
al. 2012 
(9)
Ranawaka 
2014 (7)
Study design Questionnaire-
based survey
Prosp. 
(children)
Prosp. Transversal 
and 
descriptive-
associative
Prosp. Prosp. Prosp. Retrosp. Retrosp., 
interview
Observ. 
study
Patients, n 256 272 1000 110 219 100 513 200 287 290
Control group Yes No Yes No No No No No No No
Sign AA Controls AA Controls
  Nail abnormalities, % 64.1 36.6 46 19.8 NR but >26.4 29.4 10.5 44 38 24.5 9.7 9
   Pitting 29.7 6.7 33.8 13.9 1.9 NR Most 
frequent
28 NR 19.5 NR Most 
frequent
   Trachyonychia 18.0 6.7 11.7 8.3 0 NR 2nd 9 NR 3.5 NR NR
   Leukonychia 24.6 13.3 * 2.7 15.1 NR NR NR NR NR NR NR
   Red spots lunula 5.1 0 2.2 0 0 NR NR NR NR NR NR NR
   Longitudinal ridging 9.0 3.3 NR 7.8 26.4 NR 3rd 10 NR 1.5 NR NR
   Distal notching 3.5 3.3 NR 0.8 NR NR NR 2 NR NR NR NR
   Ragged cuticle NR NR NR NR NR NR NR 2 NR NR NR NR
   Beau’s lines 0.8 0 NR NR NR NR NR 2 NR NR NR NR
*Considered normal.
NR: not reported; Prosp. prospective; Retrosp.: retrospective; Observ.: observational.
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(11/30), but significantly less frequently than in patients 
with AA. The reported prevalence and incidence of nail 
involvement in AA in the literature ranges from 9.0% to 
46% (Table V) (5, 7–9, 11, 16–18). Reported incidence 
was lowest in a retrospective file study focusing on 
several clinical characteristics of 216 Korean patients 
with AAT or AAU (9). Nail signs were not specified in 
this study, but were more frequently noted in the clini-
cal file in early-onset patients with AA (16.9%) than in 
patients with late-onset AA (7.1%). A higher prevalence 
of nail abnormalities in children (46%) than in adults 
with AA (19%) was also reported by Tosti et al. (8). In 
our study the age of onset of AA did not differ between 
patients with AA with nail involvement, and those with 
AA without nail involvement. This might be due to the 
specific design of our study, which included patients who 
had been diagnosed, on a mean of 24 years previously. 
Nail abnormalities developed, on a mean of 7 years af-
ter the onset of the hair loss. This suggests that even if 
nail involvement is more present in children presenting 
with AA, nail involvement will occur in the course of 
the disease as frequently in patients with later onset AA. 
Most studies reported a lower incidence or prevalence of 
nail involvement in AA than our study. There are several 
possible explanations for this. Firstly, we reported the 
lifetime incidence of nail changes, while several other 
studies reported point-prevalence of nail changes at the 
time of the first visit to an outpatient clinic, or during a 
short period of follow-up. Secondly, our group consisted 
of patients with severe AA; almost 60% had AAU. Nail 
involvement is more frequent among patients with severe 
AA, not only in this study, but also in other reports (8, 
11, 16, 17, 7). Sharma et al. (11) reported a prevalence 
of nail dystrophy of 19.1% in their whole group, with 
a higher incidence of 49.4% in the severe forms of AA. 
Garcia-Hernandez & Rodriguez-Pichardo (16) reported 
nail changes as a risk factor for developing severe forms 
of alopecia. In the study by Gandhi et al. (17), none of 
the patients with AAF had nail changes. A third factor 
that might have affected the results is the scoring of 
nail involvement. This study used patient-reported data 
with photographs in a questionnaire. Patients themselves 
may have a low threshold for reporting abnormalities. 
The relevance of this factor is underlined by the high 
incidence of nail abnormalities reported in the control 
group (36.6%). Only one other study on nail involvement 
in AA included a control group (11). Unfortunately, the 
incidence of nail involvement in their control group was 
not all reported, but it appears to be even higher than 
in patients with AA. Nail involvement was reported in 
19.8% of patients with AA, leukonychia was present in 
15.1% of controls, and longitudinal ridges in 26.4% of 
controls.
Apart from one patient with onycholysis, only signs 
of nail matrix disease were observed in our study. The 
absence of nail bed signs, such as onycholysis and sub-
ungual hyperkeratosis, indicates that the nail matrix is 
the only site of inflammation in AA (12). The specific 
nail signs that were reported most frequently in pa-
tients with AA were pitting (29.7%), and trachyonychia 
(18.0%). Both of these were more frequent than among 
the controls. Red spots on the lunula were reported by 
fewer patients with AA (5.1%), but not at all reported 
in the control group. Patients with AAU had a signifi-
cantly higher risk of developing red spots on the lunula 
(8.1% vs. 0.9%) than did patients with AAT and AAF. 
Pitting and trachyonychia were also the most common 
nail changes in all previous studies (8, 11, 17). Sharma 
et al. (11) reported that longitudinal ridging, pigmented 
longitudinal bands, and punctate leukonychia did not 
occur more often in AA than in controls. Van der Velden 
et al. (19) has shown recently that leukonychia is a nail 
feature that is not disease-specific, which presents in 
65% of healthy subjects. Also in our patients, leukony-
chia was found as a non-specific feature. Sharma et al. 
(11) introduced terminal “V” nicks of the nail plate as 
a new change recorded in association with AA. In our 
study, 3.1% of patients with AA reported distal notching. 
However, 3.4% of controls reported the same sign. Thus, 
leukonychia and distal notcching does not appear to be a 
specific sign for AA of the nails. Three out of 274 children 
were reported by Tosti et al. (8) to experience onycho-
madesis during the acute onset of AA universalis. In our 
population, only one patient reported onychomadesis, 
making it a rare sign of AA of the nails.
Patients with AA often experience marked psycholo-
gical distress. The disease can have detrimental impact 
on patients QoL. A recent systematic review showed that 
patients with AA consistently demonstrate poor QoL sco-
res, with greater extent of scalp involvement associated 
with lower QoL (20). Health-related QoL in AA is similar 
to that of other chronic dermatological diseases, such as 
psoriasis or chronic dermatitis. Also, nail disease may 
have serious effects on QoL. For example, patients with 
psoriasis have a significantly lower QoL when the nails 
are involved than when the nails are uninvolved (21). 
Many tools have been used to assess QoL in patients 
with AA, including the Dermatology Life Quality Index 
(DLQI), Skindex-16, Short Form Health Survey (SF-36), 
and several others (20). None of these questionnaires in-
clude questions concerning nail involvement. Therefore, 
no date or scoring systems were available to access the 
contribution of nail involvement in QoL of patients with 
AA. In this study, we used the NPQ10 scale, which is a 
QoL questionnaire specifically related to the impact of 
nail impairments on QoL, developed for nail psoriasis 
(15). The results show a low impact of nail changes on 
the QoL of patients with AA with a mean score of 0.91, 
which was similar to the controls. Nail involvement in 
AA appears to be much less troublesome than in nail 
psoriasis, because the mean score in those patients was 
9.9 (22). In general, nail psoriasis is more extensive, 
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painful, and has major signs of nail bed disease, for ex-
ample onycholysis, which may cause a major handicap 
for patients, resulting in higher scores on the QoL scale. 
A more specific QoL questionnaire focusing solely on 
nail matrix signs could be designed and validated for nail 
changes in AA, but from our results it is suggested that 
nail involvement is of major importance for only a few 
individual patients with AA. 
A minority of 13.7% of patients with AA received any 
treatment for their nails. In most cases, this treatment 
was considered ineffective. Approximately one-third of 
patients with AA desire an effective treatment for their 
nails, while most considered their nail abnormalities 
too limited to justify any treatment. The unmet need for 
treatment in patients with AA is much lower compared 
with nail psoriasis patients (22), which correlates with 
the much higher impact nail involvement has in psoriasis, 
as measured by NPQ10. 
In summary, nail involvement in patients with AA is 
common and presents mostly with pitting and trachyo-
nychia. The severity of the nail changes reflects the 
severity of the disease, with red spots on the lunula as a 
predictor for severe alopecia. Impairment of QoL by nail 
involvement is limited in the majority of patients, and the 
unmet need for treatment is lower compared with nail 
psoriasis. However, the latter could be an underestima-
tion, since lack of awareness of therapeutic options may 
play a role. Nail involvement should not be overlooked 
in trials on AA, because its presence and improvement 
may be a relevant factor in individual patients. 
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